CELZ'
s Net Margin % Range Over the Past 10 Years
Min: -192066.67 Med: -22015.15 Max: 21831.82
Current: -192066.67
CELZ's Net Margin % is ranked worse than 98.52% of 947
companies
in the Biotechnology industry
Industry Median: -89.33
vs CELZ: -192066.67
Creative Medical Technology Holdings (NAS:CELZ) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Creative Medical Technology Holdings Net Margin % Related Terms
Creative Medical Technology Holdings Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings Net Margin % Chart
For the Biotechnology subindustry, Creative Medical Technology Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Creative Medical Technology Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings (CELZ) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Creative Medical Technology Holdings and its competitors. According to the industry distribution chart, Creative Medical Technology Holdings ranks #933 out of 947 companies in the Biotechnology industry, placing it in the top 98.5%.
Is Creative Medical Technology Holdings' Net Margin % too high?
Creative Medical Technology Holdings' current Net Margin % is 0.00%. Based on the distribution chart, Creative Medical Technology Holdings ranks #933 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Net Margin % compare to APM and BCLI?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #933 out of 947 companies for Net Margin %. This places Creative Medical Technology Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Creative Medical Technology Holdings and its competitors. Creative Medical Technology Holdings's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $2.01 — trading 528.1% above its estimated fair value. The current Net Margin % is 0.00%. Creative Medical Technology Holdings' overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $2.01 is trading 528.1% above its estimated GF Value™ of $0.32.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
Net Margin %: 0.00%
GF Value™: $0.32 vs. price of $2.01 (528.1% above fair value)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
36GF Score
Get the complete analysis for CELZ
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
